About Passage Bio
Passage Bio Inc is a preclinical stage genetic medicines company. The Company is focused on developing transformative therapies for rare, monogenic central nervous system (CNS). The Company is developing a portfolio of six life transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The Company's products pipeline includes PBGM01 for the treatment of gangliosidosis (GM1), PBFT02 for the treatment of frontotemporal dementia (FTD), and PBKR03 for the treatment of Krabbe disease. The Company’s products PBGM01, utilizes an AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal beta-galactosidase (beta-gal), PBFT02, utilizes an AAV1 capsid to deliver to the brain a functional GRN gene encoding progranulin (PGRN), and PBKR03, utilizes an AAVhu68 capsid to deliver to the brain and peripheral tissues a functional gene encoding the hydrolytic enzyme galactosylceramidase (GALC).